{
    "Trade/Device Name(s)": [
        "Lucica Glycated Albumin-L",
        "Lucica\u00ae Glycated Albumin-L"
    ],
    "Submitter Information": "Asahi Kasei Pharma Corporation",
    "510(k) Number": "K170147",
    "Predicate Device Reference 510(k) Number(s)": [
        "K023763"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LCP"
    ],
    "Summary Letter Date": "September 12, 2017",
    "Summary Letter Received Date": "September 12, 2017",
    "Submission Date": "October 9, 2017",
    "Regulation Number(s)": [
        "21 CFR 864.7470"
    ],
    "Regulation Name(s)": [
        "Glycosylated hemoglobin assay"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glycated albumin"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Roche/Hitachi Modular P Chemistry system"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic assay"
    ],
    "Methodologies": [
        "Enzymatic assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Lucica Glycated Albumin-L enzymatic assay for quantitative measurement of glycated albumin in human serum to monitor glycemic control in diabetes patients",
    "Indications for Use Summary": "Quantitative measurement of glycated albumin in human serum for intermediate term monitoring of glycemic control in patients with diabetes using compatible clinical chemistry analyzers",
    "fda_folder": "Hematology"
}